Sign In
Buy PACB
$1.45
-0.180 (-11.04%)
At Close: Jun 05, 2026
Pacific Biosciences of California Target of Unusually Large Options Trading (NASDAQ:PACB)
01:14am, Tuesday, 23'rd Dec 2025
Pacific Biosciences of California, Inc. (NASDAQ: PACB - Get Free Report) was the target of some unusual options trading on Monday. Stock traders acquired 8,267 call options on the stock. This represen
PacBio to Participate in the Piper Sandler 37th Annual Healthcare Conference
09:05am, Friday, 28'th Nov 2025
MENLO PARK, Calif., Nov. 28, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will participate
Brokerages Set Pacific Biosciences of California, Inc. (NASDAQ:PACB) Price Target at $2.00
02:16am, Saturday, 22'nd Nov 2025
Pacific Biosciences of California, Inc. (NASDAQ: PACB - Get Free Report) has earned a consensus recommendation of "Hold" from the seven analysts that are presently covering the firm, MarketBeat Rating
Pacific Biosciences of California (NASDAQ:PACB) Shares Cross Above 200 Day Moving Average – Here’s Why
02:58am, Wednesday, 19'th Nov 2025
Pacific Biosciences of California, Inc. (NASDAQ: PACB - Get Free Report)'s share price crossed above its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $1.
Top 3 Genomics Stocks to Consider for Your Portfolio
09:51am, Tuesday, 18'th Nov 2025
Genomics gains momentum as EDIT, SANA, and PACB emerge as standout picks amid rapid advances in sequencing and gene editing.
Pacific Biosciences (PACB) Upgraded to Buy: Here's Why
01:01pm, Thursday, 13'th Nov 2025
Pacific Biosciences (PACB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
PACB Stock Down Despite Q3 Earnings Beat Estimates, Revenues Down Y/Y
02:21pm, Thursday, 06'th Nov 2025
PacBio posts a narrower Q3 loss and margin gains, but shares fall as revenues dip amid softer instrument demand.
Pacific Biosciences of California, Inc. (PACB) Q3 2025 Earnings Call Transcript
09:41pm, Wednesday, 05'th Nov 2025
Pacific Biosciences of California, Inc. ( PACB ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Christian Henry - President, CEO & Director James Gibson - Chief Financial Offi
Compared to Estimates, Pacific Biosciences (PACB) Q3 Earnings: A Look at Key Metrics
07:31pm, Wednesday, 05'th Nov 2025
Although the revenue and EPS for Pacific Biosciences (PACB) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare w
Pacific Biosciences of California (PACB) Reports Q3 Loss, Lags Revenue Estimates
06:56pm, Wednesday, 05'th Nov 2025
Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to a loss of $0.17 per share a year ago
HiFi Solves Consortium Publishes First Major Study Demonstrating the Clinical Research Power of PacBio HiFi Genomes
09:05am, Wednesday, 05'th Nov 2025
New multi-center study identifies 100% of clinically relevant variants in the study, including those not detected by short-read sequencing technologies, positioning HiFi as the bridge between research
Pacific Biosciences (PACB) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
10:15am, Tuesday, 04'th Nov 2025
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Pacific Biosciences (PACB), delve into some of its key metrics to gain a deeper insight into the company's potential performance
PacBio Supports Berry Genomics in Achieving First Regulatory Approval for Clinical Long-Read Sequencing in China
09:05am, Tuesday, 04'th Nov 2025
NMPA approval on the Sequel II CNDx system enables clinicians in China to harness PacBio HiFi sequencing for challenging conditions, with initial offering for thalassemia NMPA approval on the Sequel I
Sumitomo Mitsui Trust Group Inc. Trims Position in Pacific Biosciences of California, Inc. $PACB
04:06am, Thursday, 30'th Oct 2025
Sumitomo Mitsui Trust Group Inc. cut its holdings in shares of Pacific Biosciences of California, Inc. (NASDAQ: PACB) by 3.6% during the undefined quarter, according to its most recent Form 13F filing
Pacific Biosciences of California (PACB) Stock Drops Despite Market Gains: Important Facts to Note
07:16pm, Tuesday, 28'th Oct 2025
Pacific Biosciences of California (PACB) concluded the recent trading session at $1.97, signifying a -5.74% move from its prior day's close.
